Article

EyeCare America receives $1.125 million grant

San Francisco-EyeCare America, the public service program of the Foundation of the American Academy of Ophthalmology (FAAO), received a $1.125 million grant from Alcon Laboratories Inc., Fort Worth, TX.

San Francisco-EyeCare America, the public service program of the Foundation of the American Academy of Ophthalmology (FAAO), received a $1.125 million grant from Alcon Laboratories Inc., Fort Worth, TX.

The 5-year unrestricted grant will support EyeCare America's Senior EyeCare program, which bridges the health-care gap for an aging U.S. population. Through the program those who are eligible receive a dilated medical examination and up to 1 year of treatment at no out-of-pocket cost.

Today, more than two-thirds of visually impaired adults in the United States are over 65 years of age. The prevalence of blindness increases rapidly in the later years, particularly after age 75. The number of Americans with age-related eye disease is expected to double within the next 3 decades unless something is done to reverse the trend.

"Alcon is delighted to support this most worthwhile program," said Cary Rayment, Alcon's president and chief executive officer. "As a company, we have a commitment to give back to the community, and partnering with the Seniors EyeCare Program is an excellent way to fulfill that commitment."

To determine if a person qualifies for a referral, call the toll-free helpline 800/ 222-EYES (3937), which is available 24 hours a day, every day throughout the year.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.